期刊
MULTIPLE SCLEROSIS JOURNAL
卷 8, 期 2, 页码 130-138出版社
SAGE PUBLICATIONS LTD
DOI: 10.1191/1352458502ms776oa
关键词
demyelination; DM20; multiple sclerosis; paclitaxel; remyelination
Treatment with paclitaxel by four intraperitoneal injections (20 mg/kg) 1 week apart attenuated clinical signs in a spontaneously demyelinating model, if given with onset of clinical signs. If given at 2 months of age (1 month prior to clinical signs), disease was almost completely prevented. The astrogliosis, prominent in our model, was reversed by paclitaxel as determined by astrocyte counts and quantitation of GFAP. Electron microscopic examination of affected regions at 2.5 months demonstrated that the myelin was generally normal. By 4 months of age, demyelination was common in the superior cerebellar peduncle, maximal at 6 months, but continued to 8 months, In addition to myelin vocuolotion and nude axons, the presence of many thin myelin sheaths suggested remyelination or partial demyelination. Although no evidence of oligodendrocyte loss was seen, nuclear changes were observed. To substantiate that remyelination was occurring, we measured MBP (18.5 kDa), MBP-exon II, Golli-MBP, TP8, Golli-MBP-J37, platelet-derived growth factor alpha (PDGFRalpha) and sonic hedgehog (SHH). Of these TP8, PDGFRalpha, and SHH were up-regulated in the untreated transgenic After paclitaxel treatment MBP-Exon II, TP8, PDGFRalpha and SHH were further up-regulated. We concluded that some of the effects of paclitaxel were to stimulate proteins involved in early myelinating events possibly via a signal transduction mechanism.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据